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1. INTRODUCTION {#gps4839-sec-0007}
===============

Approximately 60% of nursing home (NH) patients experience nightime sleep disturbances,[1](#gps4839-bib-0001){ref-type="ref"}, [2](#gps4839-bib-0002){ref-type="ref"} and 50 to 80% of NH patients have dementia.[3](#gps4839-bib-0003){ref-type="ref"}, [4](#gps4839-bib-0004){ref-type="ref"}, [5](#gps4839-bib-0005){ref-type="ref"} Previous studies have reported that NH patients with dementia have more disturbed nightime sleep compared with NH patients without dementia.[6](#gps4839-bib-0006){ref-type="ref"} The capacity to maintain either sleep or wakefulness is further impaired as dementia progresses.[6](#gps4839-bib-0006){ref-type="ref"} Sleep disturbances among NH patients can be attributed to medical disorders, polypharmacy,[7](#gps4839-bib-0007){ref-type="ref"} pain,[8](#gps4839-bib-0008){ref-type="ref"}, [9](#gps4839-bib-0009){ref-type="ref"} and depression.[2](#gps4839-bib-0002){ref-type="ref"}, [10](#gps4839-bib-0010){ref-type="ref"} Sleep disturbances in this population may have serious consequences, as they increase the risk of falls[11](#gps4839-bib-0011){ref-type="ref"} and hip fractures,[12](#gps4839-bib-0012){ref-type="ref"}, [13](#gps4839-bib-0013){ref-type="ref"} decrease survival,[14](#gps4839-bib-0014){ref-type="ref"} and impair daytime functioning (eg, reduced memory, concentration, reaction time, and loss of autonomy).[15](#gps4839-bib-0015){ref-type="ref"}

Studies indicate that approximately 20 to 30% of NH patients have depression.[16](#gps4839-bib-0016){ref-type="ref"} The close interrelation between pain and depression is often referred to as the pain‐depression dyad.[17](#gps4839-bib-0017){ref-type="ref"} This implies that both conditions share common signal pathways and neurotransmitters and that they are responsive to comparable treatments.[17](#gps4839-bib-0017){ref-type="ref"} Depression is also associated with sleep disturbances, especially among people with cognitive impairment.[18](#gps4839-bib-0018){ref-type="ref"}, [19](#gps4839-bib-0019){ref-type="ref"} Previous research suggests overlapping neural networks for depression, sleep disturbance, and dementia.[20](#gps4839-bib-0020){ref-type="ref"} Among various neuropsychiatric symptoms, sleep and depressive symptoms are often considered to coincide as a "mood‐cluster."[21](#gps4839-bib-0021){ref-type="ref"}

Pain represents an important cause of poor sleep for people with and without dementia.[22](#gps4839-bib-0022){ref-type="ref"} Previous studies indicate that there is a bidirectional relationship between pain and sleep disturbances.[23](#gps4839-bib-0023){ref-type="ref"} Approximately 60% of NH patients experience pain every day.[24](#gps4839-bib-0024){ref-type="ref"} The prevalence may vary, however, as pain can be difficult to evaluate in people with dementia, who have reduced ability to describe their symptoms. It is therefore important that NH staff seek to identify pain through appropriate methods[25](#gps4839-bib-0025){ref-type="ref"} and exclude pain as a factor contributing to sleep disturbances before prescribing sleep medications. Overall, the presence of pain, dementia, and depression, together with sleep disturbances, may lead to a downward spiral regarding health and well‐being.[15](#gps4839-bib-0015){ref-type="ref"}, [19](#gps4839-bib-0019){ref-type="ref"}

In a cluster‐randomized clinical trial conducted by Husebo et al,[26](#gps4839-bib-0026){ref-type="ref"} a stepwise protocol of treating pain was found to improve mood, sleep, and depression in people with dementia and agitation. The study did, however, not include objective sleep measurements and was not placebo‐controlled. Consequently, the aim of the present study was to investigate the effect of pain treatment on sleep in NH patients with dementia and depression in a placebo‐controlled randomized clinical trial with objective sleep measurements.

We hypothesized that pain treatment would improve total sleep time (TST), sleep efficiency (SE), sleep onset latency (SOL), waking after sleep onset, early morning awakening (EMA), and number of bouts awake. In addition, we conducted several subgroup analyses. In 1 subgroup analysis, the aim was to investigate the effects of pain treatment on different sleep outcomes for patients with poor sleep at baseline, defined as SE \< 85%. In a second analysis, the aim was to investigate if pain treatment improved sleep more in patients who were in pain at baseline, defined as Mobilization‐Observation‐Behaviour‐Intensity‐Dementia‐2 Pain Scale (MOBID‐2) score ≥ 3. In a final analysis, we aimed to investigate if there were any differences within the active treatment group, ie, between patients receiving active buprenorphine and active placebo, respectively.

 {#gps4839-sec-0005}

###### Key points

Sleep disturbances are very common among people with dementia.Compared with placebo, pain treatment improved sleep in NH patients with dementia and depression, as measured by actigraphy.Sleep, pain, and depression in NH patients should be evaluated systematically, and pain treatment should be considered as a potentially beneficial treatment.

2. METHODS {#gps4839-sec-0008}
==========

This study used data collected in the period from 1 week before the intervention until 1 week after the intervention. The study is part of a 13‐week, multicenter, parallel‐group, double‐blind, placebo‐controlled randomized trial: "Efficacy of Pain Treatment on Depression in Patients with Dementia---A Randomized Clinical Trial of Efficacy: DEP.PAIN.DEM." The study was conducted in Norway from August 2014 to September 2016.

The NHs were located in 11 municipalities in both urban and rural areas and both larger and smaller Norwegian towns. Data collection was conducted by 2 researchers, who recruited NHs through direct contact with NH management. Inclusion and exclusion criteria are listed in Table [1](#gps4839-tbl-0001){ref-type="table-wrap"}. At the participating NHs, the researchers were granted access to patient medical records to perform prescreening. In cases where no recent (\<14 days old) blood analyses (electrolytes, hemoglobin, serum creatinine, and serum alanine aminotransferase) were available, new analyses were requisitioned. Patients who were not excluded in the medical record review were screened for depression by using the Cornell Scale for Depression in Dementia (CSDD)[27](#gps4839-bib-0027){ref-type="ref"} and for dementia by using the Mini‐Mental State Examination (MMSE).[28](#gps4839-bib-0028){ref-type="ref"} If the inclusion criteria (CSDD ≥ 8 and MMSE \< 20) were fulfilled, the patient was reassessed after written consent had been given. A drop from ≥8 to ≥6 in CSDD was permitted between screening and baseline. If a patient fulfilled all of the inclusion criteria and none of the exclusion criteria, and inclusion and study treatment were approved by the physician responsible for the patient, the patient was enrolled in the study (see the flow chart in Figure [1](#gps4839-fig-0001){ref-type="fig"} for an overview of enrolment and reasons for exclusion).

###### 

Inclusion and exclusion criteria in the actigraphy subproject

  Inclusion Criteria   Age ≥ 60 years
  -------------------- --------------------------------------------------------------------------------------------------
                       Long‐term nursing home placement with \>4‐week stay
                       Dementia (MMSE ≤ 20)
                       Depression (CSDD ≥ 8, \>3‐week duration)
  Exclusion criteria   Life expectancy \< 6 months
                       Severe medical disease that could interfere with study participation
                       Severe liver and/or renal impairment
                       Anemia (Hb \< 8.5 mmol/L) or electrolyte imbalance (Na+ and K+)
                       Suicide risk (any attempts during the last year)
                       History of severe psychiatric disease prior to dementia onset
                       Severe aggression (NPI‐NH aggression item score ≥ 8, with aggression as the predominant symptom)
                       Severe pain (MOBID‐2 ≥ 7)
                       Uncontrolled epilepsy
                       Contraindication or clinically significant drug interaction to the assigned study treatment
                       Change in psychotropic drugs
                       Regular use of any opioid analgesic other than, or exceeding, buprenorphine 5 mcg/h
                       Did not want to wear an actigraph
                       Immobile patients (paralysis, or otherwise bedridden)
                       Patients with involuntary movement (eg, Parkinson disease)
                       Less than 5 nights of actigraphy recordings

Abbreviations: CSDD indicates Cornell Scale for Depression in Dementia; MMSE, Mini‐Mental State Examination; MOBID‐2, Mobilization‐Observation‐Behaviour‐Intensity‐Dementia‐2 Pain Scale; NPI‐NH, Neuropsychiatric Inventory‐Nursing Home Version.

![Flow chart screening and inclusion](GPS-33-663-g001){#gps4839-fig-0001}

A fixed‐dose regimen was used in the study period. The patients were offered a 1‐g tablet/placebo at breakfast, lunch, and supper (8 a.m. noon and 6 p.m.). The patients received a stepwise pain treatment, in which those who were taking paracetamol ≤1 g/day prior to inclusion were allocated to paracetamol tablets/placebo tablets. The study treatment was prescribed in addition to the basic dose. Patients who were taking nonopioid analgesics/paracetamol \>1 g/day, and/or NSAID/buprenorphine, but had difficulty with swallowing tablets were assigned to the buprenorphine/placebo transdermal system. In line with the administrative guidelines, the buprenorphine transdermal patch/placebo patch was changed on a fixed day every week. For patients who were taking buprenorphine transdermal 5 μg/h prior to inclusion, the study treatment was given as an additional 5‐μg/h transdermal patch (active or placebo). After inclusion, all patients continued their usual medical treatment (including any regular or "as needed" \[PRN\] analgesic). To ensure stability and control in the study, the clinicians were advised to keep doses of psychotropic and analgesic drugs unchanged during the study period. If any clinical changes occurred, eg, new conditions or injuries, they were to be treated adequately. All withdrawals and reasons were registered.

All sleep‐related outcomes were assessed with Actiwatch Spectrum (Philips Respironics). Activity was registered continuously for 14 consecutive days, during which the intervention started on day 8. Data were thus recorded for all sleep parameters for duration of 1 week before and 1 week after the study treatment commenced. The actigraphs were placed on the dominant/mobile wrist. To enable better scoring of the patients\' actual time spent in bed, the NH staff were instructed (verbally and written) to register bedtimes and rising times by pushing the event button on the actigraph (light off/lights on).

The Actiware 6 (Respironics) was used for sleep scoring. Sensitivity was set to medium, and sleep/waking status was determined for each 1‐minute epoch. A trained technician scored all the activity protocols. A standardized hierarchical approach was used to set rest intervals for the actigraphy data, using (1) event markers when possible, or (2) light and activity data, or (3) light or activity data. Alternatives 2 and 3 were only implemented if there was a clear differentiation between active and rest periods; if not, the actigraphy protocol was excluded.

Depression was assessed by using the validated CSDD. The CSDD consists of 19 items measuring 5 domains of depression (mood, behavioral disturbances, physical signs, cyclic functions, and ideational disturbances). A cut‐off point of 8/9 has demonstrated the best accuracy for diagnosing depression according to the International Statistical Classification of Diseases and Related Health Problems 10th Edition criteria.[27](#gps4839-bib-0027){ref-type="ref"} The assessment was conducted by using only information provided by NH staff members who knew the resident very well.

Pain was assessed by the MOBID‐2, a validated staff‐administered instrument for measuring pain in people with advanced dementia.[25](#gps4839-bib-0025){ref-type="ref"} The instrument provides a total score based on all of the observations ranging from 0 to 10, where 10 represents the worst possible pain.[25](#gps4839-bib-0025){ref-type="ref"} A score of ≥3 has been used as a cut‐off to indicate clinically relevant pain.[25](#gps4839-bib-0025){ref-type="ref"}

Cognitive function was assessed by using the validated MMSE.[28](#gps4839-bib-0028){ref-type="ref"} The MMSE is a brief, cognitive screening test with a 30‐point scale that consists of 20 tasks and was developed to distinguish potential dementia from normal functioning.[29](#gps4839-bib-0029){ref-type="ref"} Five patients started the MMSE screening and scored very poorly and subsequently withdrew from the MMSE screening. This led to missing data. For these patients, cognitive function was assessed by proxy through conversations with primary doctors and nurses as an alternative to MMSE screening.

The patients were randomly allocated to each arm in a 1:1 ratio, using computer‐generated random numbers. The randomization list was produced by a statistician, without any involvement of the research team. There was no use of stratification factors. The research team was provided with a blinded, sequential list of pack identification numbers, and the patients were consecutively assigned to the next pack number in the list upon inclusion. The study was double‐blinded, and all researchers, patients, and NH staff were masked regarding the group allocation.

Descriptive statistics were calculated for all relevant variables. Comparisons of sleep parameters pre‐ and posttreatments were performed as a mixed within‐between subjects ANOVA (placebo versus active treatment and pretreatment versus posttreatment). Differences between pre‐ and posttreatments within each treatment group were assessed with paired *t* tests for each of the experimental groups separately. Furthermore, we conducted additional 2 × 2 mixed within‐between subjects ANOVA analyses. One of these analyses investigated patients who had sleep disturbances at baseline, defined as SE \< 85%,[30](#gps4839-bib-0030){ref-type="ref"} and compared the effect of active and placebo treatments for those patients. A second analysis compared the effect of the treatments for a subgroup of patients whose MOBID‐2 score was ≥3, ie, patients who had pain at baseline. The last analysis investigated patients in the active treatment group and thus compared the effect of active buprenorphine to that of active paracetamol. The statistical analyses were conducted by using IBM SPSS Statistics 22.

Each patient\'s medical decision‐making capacity was discussed with the patient\'s primary nurse at the NH. Attempts were made to adjust the information for patients who had reduced capacity to give consent (MMSE score from 16 to 19).[31](#gps4839-bib-0031){ref-type="ref"} In addition, the researchers contacted all of the eligible patients\' legal guardians. If the legal guardians gave presumed consent on behalf of the patient, they received written and oral information together with a consent form that they signed and mailed back. The study was approved by the Regional Ethics Committee (REC‐West 2013/1474). The study\'s clinical trial number is NCT02267057.

3. RESULTS {#gps4839-sec-0009}
==========

In total, 2323 patients were screened for eligibility, of whom 162 were eligible to participate as part of the broader study. The final sample of the actigraphy subproject included 106 participants (see Figure [1](#gps4839-fig-0001){ref-type="fig"}). Of the 106 patients, 49 were randomly assigned to the placebo group and 57 to the active treatment group. In the active treatment group, 2 patients dropped out due to their reaction to the treatment. In the total sample of patients with actigraphs, the mean age was 85.5 years (SD = 7.3), 76% were female, the mean CSDD score was 11.2 (SD = 3.7), the mean MMSE score was 7.6 (SD = 6.0), the mean MOBID‐2 score was 2.8 (SD = 2.1), and 54.7% had a MOBID‐2 score ≥ 3. Sleep characteristics pre‐ and posttreatments for patients in both experimental groups, as well as the interaction effect for each sleep outcome, are shown in Table [2](#gps4839-tbl-0002){ref-type="table-wrap"}.

###### 

Within‐ and between‐group effects of the placebo and active treatments on different sleep outcomes

               Placebo Group (n = 49)        Active Group (n = 55)   Interaction Effect[c](#gps4839-note-0005){ref-type="fn"}                                                      
  ------------ ----------------------------- ----------------------- ---------------------------------------------------------- ----------------------------- ------ ------ ------ ------
  TST (min)    509.9 (113.6)‐498.8 (126.5)   .164                    0.20                                                       515.6 (136.7)‐526.9 (119.7)   .235   0.16   3.25   .074
  SE (%)       70.0 (13.1)‐67.5 (14.8)       .036                    0.31                                                       69.9 (14.8)‐72.2 (12.5)       .039   0.29   9.11   .003
  SOL (min)    47.0 (44.5)‐59.6 (80.3)       .187                    0.19                                                       31.7 (35.2)‐24.6 (28.2)       .079   0.24   4.03   .047
  WASO (min)   140.6 (68.3)‐143.3 (68.3)     .610                    0.07                                                       136.0 (66.7)‐134.5 (58.2)     .800   0.03   0.27   .604
  EMA (min)    30.7 (38.9)‐35.2 (35.5)       .268                    0.16                                                       50.1 (61.1)‐40.5 (37.5)       .082   0.24   4.20   .043
  NoW (no.)    31.2 (11.6)‐30.3 (11.8)       .404                    0.12                                                       30.0 (11.9)‐29.4 (13.5)       .551   0.08   0.05   .831

*Notes*: TST indicates total sleep time; SE, sleep efficiency; SOL, sleep onset latency; WASO, waking after sleep onset; EMA, early morning awakening; NoW, number of bouts awake.

Paired *t* test, comparing values before and after the intervention (separate tests for the placebo group and the active group).

Effect size (Cohen\'s *d*) for paired values.

A mixed within‐between subjects 2 × 2 ANOVA comparing the placebo and active treatments.

Pre = −7 to 0 days (baseline).

Post = 1 to 7 days active/placebo treatment.

In the total sample (n = 106), SE, SOL, and EMA all improved for the active treatment group compared with the placebo group (see Table [2](#gps4839-tbl-0002){ref-type="table-wrap"}). The analysis of the treatment for the subgroup of patients with preexisting sleep disturbances (SE \< 85%) identified at baseline (n = 89) confirmed the main effects (see Table [3](#gps4839-tbl-0003){ref-type="table-wrap"}). In addition, TST improved significantly for the active treatment group compared with the placebo group (see Table [3](#gps4839-tbl-0003){ref-type="table-wrap"}). Interestingly, when analyzing the effect of treatment for the subgroup of patients who experienced pain at baseline (n = 46), we found no significant differences between active and placebo treatment for any of the sleep outcomes (see Table [4](#gps4839-tbl-0004){ref-type="table-wrap"}). In a final analysis, we investigated if there were any differences within the active treatment group (see Table [5](#gps4839-tbl-0005){ref-type="table-wrap"}). We found a significant increase in TST for patients who received active buprenorphine compared with those who received active paracetamol (see Table [5](#gps4839-tbl-0005){ref-type="table-wrap"}).

###### 

Effects of the placebo and active treatments on different sleep outcomes for patients with SE \< 85%

               Group With SE Below 85% (n = 89)                                                                     
  ------------ ---------------------------------- ------ ------ ----------------------------- ------ ------ ------- ------
  TST (min)    488.8 (97.6)‐475.3 (108.1)         .107   0.25   477.7 (114.6)‐497.6 (103.9)   .065   0.28   6.25    .014
  SE (%)       67.5 (11.3)‐64.9 (13.3)            .049   0.30   65.4 (12.4)‐69.0 (10.8)       .005   0.44   12.18   .001
  SOL (min)    51.9 (44.4)‐66.0 (82.4)            .182   0.20   37.3 (36.5)‐28.2 (29.7)       .063   0.28   4.17    .044
  WASO (min)   150.7 (63.9)‐153.5 (63.5)          .635   0.07   154.4 (58.3)‐148.7 (50.3)     .432   0.12   0.83    .363
  EMA (min)    33.7 (40.0)‐37.2 (36.3)            .418   0.12   58.5 (64.5)‐45.6 (39.1)       .049   0.30   4.51    .036
  NoW (no.)    31.7 (11.6)‐30.5 (11.4)            .339   0.15   32.5 (10.6)‐31.5 (12.3)       .365   0.14   0.00    .957

*Notes*: TST indicates total sleep time; SE, sleep efficiency; SOL, sleep onset latency; WASO, waking after sleep onset; EMA, early morning awakening; NoW, number of bouts awake.

Paired *t* test, comparing values before and after the intervention (separate tests for the placebo group and the active group).

Effect size (Cohen\'s *d*) for paired values.

A mixed within‐between subjects 2 × 2 ANOVA comparing the buprenorphine and paracetamol groups for the patients with poor sleep efficiency.

Pre = −7 to 0 days (baseline).

Post = 1 to 7 days active/placebo treatment.

###### 

Effects of the placebo and active treatments on different sleep outcomes for patients with pain (MOBID‐2 ≥ 3) at baseline

               Group With Pain (n = 46)                                                                       
  ------------ ----------------------------- ------ ------ ----------------------------- ------ ------ ------ ------
  TST (min)    518.3 (126.0)‐523.8 (130.7)   .528   0.13   554.4 (141.8)‐565.2 (127.8)   .223   0.27   0.18   .667
  SE (%)       70.3 (14.9)‐69.4 (14.4)       .330   0.20   74.1 (14.5)‐75.7 (13.6)       .122   0.35   3.56   .066
  SOL (min)    42.5 (44.7)‐49.5 (66.9)       .413   0.17   25.1 (26.5)‐23.0 (24.9)       .611   0.11   0.84   .362
  WASO (min)   137.7 (67.1)‐140.4 (75.0)     .737   0.07   128.2 (73.5)‐124.7 (70.4)     .683   0.09   0.28   .595
  EMA (min)    37.3 (51.4)‐36.7 (39.7)       .906   0.02   34.0 (36.4)‐29.9 (30.2)       .276   0.24   0.34   .559
  NoW (no.)    31.3 (12.7)‐30.1 (13.3)       .407   0.17   29.7 (14.2)‐30.5 (15.6)       .623   0.11   0.88   .351

*Notes*: TST indicates total sleep time; SE, sleep efficiency; SOL, sleep onset latency; WASO, waking after sleep onset; EMA, early morning awakening; NoW, number of bouts awake.

Paired *t* test, comparing values before and after the intervention (separate tests for the placebo group and the active group).

Effect size (Cohen\'s *d*) for paired values.

A mixed within‐between subjects 2 × 2 ANOVA comparing the placebo and active treatments for the patients with pain (MOBID‐2 score ≥ 3).

Pre = −7 to 0 days (baseline).

Post = 1 to 7 days active/placebo treatment.

###### 

Effects of the placebo and active treatments on different sleep outcomes for patients given active buprenorphine and paracetamol

               Group With Active Treatment (n = 55)                                                                     
  ------------ -------------------------------------- ------ ------ ----------------------------- ------ ------ ------- ------
  TST (min)    531.5 (145.5)‐518.3 (131.4)            .233   0.24   502.3 (129.9)‐534.0 (110.9)   .029   0.42   6.176   .016
  SE (%)       72.2 (14.1)‐72.4 (12.7)                .854   0.04   68.0 (15.4)‐72.1 (12.6)       .027   0.42   3.252   .077
  SOL (min)    34.0 (35.5)‐29.0 (33.5)                .238   0.24   29.8 (35.4)‐20.9 (22.8)       .181   0.25   0.241   .626
  WASO (min)   121.3 (63.8)‐123.6 (52.8)              .762   0.06   148.3 (67.7)‐143.5 (61.7)     .610   0.09   0.333   .566
  EMA (min)    42.9 (47.4)‐39.7 (39.7)                .562   0.12   56.1 (70.8)‐41.2 (36.2)       .101   0.31   1.173   .284
  NoW (no.)    28.5 (11.8)‐28.4 (13.6)                .969   0.01   31.3 (12.1)‐30.2 (13.6)       .464   0.14   0.244   .624

*Notes*: TST indicates total sleep time; SE, sleep efficiency; SOL, sleep onset latency; WASO, waking after sleep onset; EMA, early morning awakening; NoW, number of bouts awake.

Paired *t* test, comparing values before and after the intervention (separate tests for the buprenorphine group and the paracetamol group).

Effect size (Cohen\'s *d*) for paired values.

A mixed within‐between subjects 2 × 2 ANOVA comparing the buprenorphine and paracetamol groups for the patients who received active treatment.

Pre = −7 to 0 days (baseline).

Post = 1 to 7 days active/placebo treatment.

4. DISCUSSION {#gps4839-sec-0010}
=============

The results of the present study gave partial support to our hypotheses. The study demonstrated that active pain treatment for people with dementia and depression improved 3 central sleep parameters: SE, SOL, and EMA. When we analyzed the subgroup with poor sleep at baseline, the results were further strengthened, with an additional improvement in TST. Moreover, the group of patients who received the active buprenorphine transdermal patch had significantly longer TST compared with the active paracetamol group. However, being in pain at baseline was not associated with improved sleep after active treatment.

To the best of our knowledge, this is the first placebo‐controlled randomized clinical trial to investigate the efficacy of pain treatment on sleep among NH patients with dementia and depression. The study is of key importance for clinicians, because it provides new insight into the complex and poorly understood relationship among pain, depression, and sleep. There is a great need for such insight, because sleep disturbances are endemic among NH patients, and knowledge regarding potential treatment is essential.

Even though the underlying mechanisms of the results are unknown and the clinical value of the treatment effect is uncertain, the results indicate that pain treatment may contribute to improved sleep among some NH patients with dementia and depression. As described above, there were patients already receiving pain medication (paracetamol) prior to inclusion. However, our results suggest that some of the patients might not be adequately treated, with paracetamol alone or only with a low dose. Therefore, these patients may experience beneficial effects of stronger medication (eg, buprenorphine) or an increased dose of already prescribed medication.

Interestingly, when we conducted subgroup analyses of the patients with sleep disturbances (defined as SE \< 85%), we found significant improvement in TST in addition to SE, SOL, and EMA, indicating that the group of patients with poor sleep might derive greater benefit from pain treatment. Husebo et al[32](#gps4839-bib-0032){ref-type="ref"} found that a systematic approach to pain management significantly reduced agitation among people with dementia and agitation. In a different study, also conducted by Husebo et al,[26](#gps4839-bib-0026){ref-type="ref"} the results showed that mood symptoms, including depression and sleep disturbances, improved with pain treatment in the same patient group. This was partly attributed to potentially untreated pain.[26](#gps4839-bib-0026){ref-type="ref"}, [32](#gps4839-bib-0032){ref-type="ref"} Interestingly, in the present study, we found no improvements in sleep in the subgroup of patients in pain at baseline. Thus, the results do not support that the underlying mechanism is untreated pain. It should be noted that the subgroup analysis only included 21 patients with active treatment and pain according to MOBID‐2. The lack of significant differences could therefore be due to the low sample size. It is noteworthy, however, that Zanocchi et al[33](#gps4839-bib-0033){ref-type="ref"} found no association between sleep problems and the presence of pain, although pain intensity was associated with patients\' sleep disturbances.

Furthermore, the results showed that TST increased significantly among patients who received active buprenorphine compared with patients who received active paracetamol. Because sedation is a frequently reported opioid‐associated side effect, which is more likely to occur at the onset of therapy or with dose increase,[34](#gps4839-bib-0034){ref-type="ref"} this may suggest an opioid‐associated sedation effect. Actigraphy only records movement, and a total lack of movement would therefore be assessed as sleep. It is not possible to examine the question of whether there is a sedation effect further with this study design.

In the present study, the NH patients wore the actigraph on the dominant or mobile wrist. This choice was made because many NH patients have limited mobility, due to medical conditions (eg, stroke or paralysis) or general fragility and inactivity. Therefore, potential activity would more likely to occur first in the dominant or mobile wrist. This implies that wearing the actigraph on the dominant wrist increases the probability of activity to be registered. There are no standards regarding the placement (dominant/nondominant wrist) of the actigraph.[35](#gps4839-bib-0035){ref-type="ref"} However, in prior studies on persons with dementia, the dominant wrist is most commonly used. For instance, Camargos et al[35](#gps4839-bib-0035){ref-type="ref"} recommended using the dominant or mobile wrist. It would, however, be valuable to assess the potential differences between measurements on the nondominant versus the dominant wrist in future research.

The results should be interpreted with caution because the study design does not allow us to assess if the improvement is of subjective value for the patient. Further research is necessary to investigate this more extensively. However, the results of this study suggest that clinicians should evaluate pain, sleep, and depression by using proper assessment tools and, based on such evaluation, consider pain treatment as potentially beneficial for patients with sleep disturbances.

5. LIMITATIONS {#gps4839-sec-0011}
==============

Our study has some limitations. The use of multiple sleep‐related outcome measures is a potential study limitation, which can potentially lead to type I errors. We do not correct for multiple comparisons in our study. However, a simple Bonferroni correction would be overly conservative and would increase the risk of type II errors.[36](#gps4839-bib-0036){ref-type="ref"} Therefore, we urge the reader to take the lack of such correction into account in the interpretation of the findings of the study.

In actigraphy recordings, immobility of the participants marks the beginning of the sleep period. Sleep onset latency has been particularly difficult to ascertain with actigraphy, because patients may just be lying still in bed and it can be recorded as sleep.[37](#gps4839-bib-0037){ref-type="ref"} In addition, previous studies show that actigraphy is less precise in differentiating between sleep and wakefulness when SE is reduced.[37](#gps4839-bib-0037){ref-type="ref"}, [38](#gps4839-bib-0038){ref-type="ref"}, [39](#gps4839-bib-0039){ref-type="ref"} Both of these factors may lead to an overestimation of sleep.

The comprehensive combination of inclusion and exclusion criteria made it difficult to recruit patients to the study. Of the 2323 patients screened for potential eligibility, a total of 895 did not have depression according to CSDD. In addition, there has been a change in the prescription of pain medication for NH patients during the last decade that influenced inclusion. Sandvik et al[40](#gps4839-bib-0040){ref-type="ref"} found that analgesic drug prescription at NHs increased significantly from 2000 to 2011, and in particular the use of paracetamol and strong opioids. This impeded the inclusion of patients in the study, as a high number of patients were already taking high doses of opioids (n = 562) and could not be included. This may have excluded some people with depression or sleep problems, who could have benefited from the study intervention. This renders the generalizability of our study questionable because our sample may not be representative for the general NH population.

Furthermore, the subgroup analysis is based on a low number of respondents, which implies that we cannot exclude type 2 errors. Another central limitation in the study is that it does not include pain assessment during the week after the intervention. As a consequence, we do not know how pain progressed after the intervention. Future research should include a larger sample of patients with pain at baseline to account for a large attrition rate and follow‐up with pain assessments after the intervention is given. A further limitation of our study was that we did not conduct a priori power analyses, which would have been beneficial for assessing if the statistical tests have sufficient power. However, our sample is similar to or larger than samples in comparable studies. The reader should, however, interpret the findings with caution, in particular for the subgroup analyses with lower sample sizes.

6. CONCLUSION {#gps4839-sec-0012}
=============

Compared with placebo, pain treatment improved actigraphy‐measured sleep in NH patients with dementia and depression. This implies that sleep, pain, and depression in NH patients should be evaluated critically and that pain treatment should be considered as a potentially beneficial treatment for residents with poor sleep. Future research should focus on the underlying mechanisms and explore the subjective value of such treatment for the NH patient.
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